Alto Neuroscience, Inc. (NYSE:ANRO) Stock Position Raised by Barclays PLC

Barclays PLC raised its position in shares of Alto Neuroscience, Inc. (NYSE:ANRO) by 872.7% in the third quarter, Holdings Channel reports. The firm owned 29,599 shares of the company’s stock after buying an additional 26,556 shares during the period. Barclays PLC’s holdings in Alto Neuroscience were worth $339,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. Federated Hermes Inc. raised its stake in shares of Alto Neuroscience by 33.3% in the 2nd quarter. Federated Hermes Inc. now owns 12,000 shares of the company’s stock valued at $128,000 after acquiring an additional 3,000 shares in the last quarter. BNP Paribas Financial Markets raised its stake in shares of Alto Neuroscience by 619.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 4,315 shares of the company’s stock valued at $49,000 after acquiring an additional 3,715 shares in the last quarter. Philadelphia Financial Management of San Francisco LLC raised its stake in shares of Alto Neuroscience by 1.5% in the 3rd quarter. Philadelphia Financial Management of San Francisco LLC now owns 449,952 shares of the company’s stock valued at $5,147,000 after acquiring an additional 6,663 shares in the last quarter. Rhumbline Advisers bought a new position in Alto Neuroscience in the 2nd quarter worth approximately $113,000. Finally, Jane Street Group LLC bought a new position in Alto Neuroscience in the 3rd quarter worth approximately $124,000.

Analysts Set New Price Targets

Several research analysts have commented on ANRO shares. Rodman & Renshaw downgraded Alto Neuroscience from a “buy” rating to a “neutral” rating in a research report on Wednesday, October 23rd. RODMAN&RENSHAW lowered Alto Neuroscience from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 23rd. William Blair reaffirmed an “outperform” rating on shares of Alto Neuroscience in a research note on Tuesday, September 10th. Stifel Nicolaus decreased their price target on Alto Neuroscience from $32.00 to $10.00 and set a “buy” rating on the stock in a research note on Wednesday, November 13th. Finally, Wedbush lowered Alto Neuroscience from an “outperform” rating to a “neutral” rating and decreased their price target for the company from $29.00 to $4.00 in a research note on Wednesday, October 23rd. Three equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $20.00.

Alto Neuroscience Stock Performance

ANRO stock opened at $4.61 on Friday. The business has a fifty day moving average of $4.15 and a 200-day moving average of $9.20. The company has a debt-to-equity ratio of 0.05, a quick ratio of 13.09 and a current ratio of 13.10. Alto Neuroscience, Inc. has a twelve month low of $3.56 and a twelve month high of $24.00.

Alto Neuroscience (NYSE:ANRO) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.62) EPS for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.05. As a group, equities research analysts predict that Alto Neuroscience, Inc. will post -2.54 earnings per share for the current fiscal year.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.